DGAP-News: Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent Prana Research
(firmenpresse) - DGAP-News: Curaxis Pharmaceutical Corp. / Key word(s): Miscellaneous
Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent
Prana Research
25.03.2011 / 18:55
---------------------------------------------------------------------
Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent Prana
Research
DURHAM, N.C., March 24, 2011 (GLOBE NEWSWIRE) -- Patrick S. Smith,
President and Chief Executive Officer of Curaxis Pharmaceutical Corp.
(OTCBB:CURX) (Frankfurt:8CX), commented today on recent research results
reported by Prana Biotechnology.
'Prana's research, in which they elaborated on changes in brain structure
in mice treated with their Alzheimer's disease candidate, underscores the
validity of new approaches to treating Alzheimer's that do not target beta
amyloid as the primary cause of the disease. Repeated failures in advanced
clinical trials have demonstrated that beta amyloid is not an effective
target for treating Alzheimer's. We extend our congratulations to Prana on
this research. Similarly, Memryte, which is our novel candidate to treat
Alzheimer's and which lowers elevated levels of luteinizing hormone (LH),
has demonstrated significant promise in treating Alzheimer's in both animal
testing and in human clinical trials. Our research indicates that our
approach works to stabilize cognition and reduce inflammation, beta amyloid
accumulation, tau phosphorylation and oxidative stress, all of which we
believe are downstream events for which elevated LH levels serve as the
catalyst. We look forward to further demonstrating the potential of Memryte
as the first disease modifying treatment for Alzheimer's as we move into
advanced clinical trials later this year,' Mr. Smith concluded.
About Curaxis
Curaxis is an emerging specialty pharmaceutical company with a hormone drug
product candidate for the treatment of Alzheimer's disease and multiple
cancers. Curaxis' therapeutic platform is based on the hypothesis that many
diseases of aging may be caused by age-related changes in the function of
the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal
endocrine feedback loop that controls development, reproduction and aging
in animals. This drug development platform is built on the premise that
hormones associated with this feedback loop are beneficial early in life,
when they promote growth and development, but are harmful later in life
when the mechanism for feedback is compromised, thereby leading to disease
processes, including pathologies associated with Alzheimer's disease and
various cancers. We believe our discovery of similar hormonal signaling
mechanisms at the cellular level in brain tissue from Alzheimer's patients
and in multiple tumors will enable us to develop significant new treatments
for Alzheimer's disease as well as many cancers.
Notice Regarding Forward Looking Statements
This press release includes certain 'Forward-Looking Statements' within the
meaning of section 21E of the Securities Exchange Act of 1934, as amended.
All statements regarding potential results and future plans and objectives
of Curaxis Pharmaceutical Corporation are forward-looking statements that
involve various risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and actual results and future
events could differ materially from those anticipated in such statements.
Important factors that could cause actual results to differ materially from
our expectations include, but are not limited to, those factors that are
disclosed under the heading 'Risk Factors' and elsewhere in our documents
filed from time to time with the Securities and Exchange Commission. Other
risk factors may include, but are not limited to, fluctuation in quarterly
results, and increased competition in our operations, our ability to
continue operations as scheduled, and our ability to protect the
proprietary technology we use. Further, the company operates in an industry
sector where securities values are highly volatile and may be influenced by
economic and other factors beyond the company's control, such as
announcements by competitors and service providers. The contents of this
press release are presented as a general overview of the company. It is
intended only to contain general information regarding the company and its
business and does not purport to provide complete disclosure or analysis of
all matters, which may be relevant to a decision to make an investment,
including all risk factors or similar considerations. Although the
information is believed current as of the date herein, the information may
be subject to change, amendment or supplementation, and the company does
not expect, and assumes no obligation, to update or otherwise revise the
information herein.
CONTACT: CURAXIS Pharmaceutical Corp.
Contact: David Corcoran
Email: dcorcoran(at)curaxispharma.com
European Advisor: Andreea Porcelli
Phone: 0035-2-2088-0289
Email: andreea.porcelli(at)contiadvisors.com
End of Corporate News
---------------------------------------------------------------------
25.03.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
117122 25.03.2011
Datum: 25.03.2011 - 18:55 Uhr
Sprache: Deutsch
News-ID 33595
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 245 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Curaxis Pharmaceutical Corp. CEO Patrick S. Smith Comments on Recent Prana Research"
steht unter der journalistisch-redaktionellen Verantwortung von
Curaxis Pharmaceutical Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
